Autoimmune Biotech Xencor Files for a $69 Million IPO

Published: Oct 11, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Xencor, a clinical-stage biotech developing treatments for severe autoimmune and allergic diseases and cancer, filed on Friday with the SEC to raise up to $69 million in an initial public offering.

Help employers find you! Check out all the jobs and post your resume.

Back to news